Drug Trial News

RSS

Nicotinamide riboside shows promise in treating Werner syndrome symptoms

Werner syndrome (WS) is a rare genetic disorder that causes premature aging and serious complications. In the first clinical trial of its kind, researchers from Japan with the company Niagen Bioscience, investigated the effects of nicotinamide riboside (NR), a vitamin B3 derivative, in patients with WS.

5 Jun 2025

New data shows zigakibart sustains proteinuria remission and kidney function in IgA nephropathy

New 100-week data from the ongoing Phase 1/2 study of zigakibart, an investigational anti-APRIL monoclonal antibody, reinforce its potential as a disease-modifying treatment for IgA nephropathy (IgAN).

5 Jun 2025

P2Y12 inhibitors linked to lower rates of cardiovascular events compared to aspirin

Giving a P2Y12 inhibitor anti-clotting drug to patients with coronary artery disease is associated with lower rates of cardiovascular death, heart attack and stroke compared with traditional aspirin, with no increased risk of major bleeding, finds a study published by The BMJ today.

5 Jun 2025

Type 2 diabetes drug shows improvements for patients with progressive liver disease

The sodium glucose cotransporter 2 (SGLT-2) inhibitor drug dapagliflozin, widely used to treat type 2 diabetes, also shows improvements for patients with progressive liver disease, finds a clinical trial from China published by The BMJ today.

5 Jun 2025

AI-designed drug shows early promise for lung fibrosis patients in clinical trial

Researchers report that rentosertib, an AI-discovered TNIK inhibitor, showed promising safety and potential to improve lung function in patients with idiopathic pulmonary fibrosis in a 12-week phase 2a clinical trial. The highest dose group demonstrated a trend toward increased forced vital capacity, especially among patients not receiving standard antifibrotic therapy, supporting further clinical investigation.

4 Jun 2025

SWOG S2302 Pragmatica-Lung study demonstrates value of streamlined clinical trials in real world settings

The SWOG S2302 Pragmatica-Lung trial, which broke new ground with its streamlined pragmatic design, unusually broad eligibility criteria, and reduced data collection, has quickly answered its primary question, finding that the investigational combination it tested did not significantly extend overall survival compared to standard of care treatments.

4 Jun 2025

Early camizestrant therapy keeps advanced breast cancer in check

Switching to camizestrant, a next-generation oral SERD, significantly prolongs progression-free survival and maintains quality of life in patients with ESR1-mutated, hormone receptor-positive advanced breast cancer. The proactive, biomarker-guided approach allows earlier intervention and may redefine standard care.

3 Jun 2025

Real world data confirms effectiveness of nirsevimab in young infants with bronchiolitis

A single dose of the long-acting antibody nirsevimab developed to prevent respiratory syncytial virus infections (The drug has been approved at the European level to protect infants in their first season of exposure to the virus) to infants can halve hospitalizations for bronchiolitis.

3 Jun 2025

PfSPZ-LARC2 malaria vaccine advances to new age groups after successful safety review

Physician-scientists at Groupe de Recherche Action en Santé (GRAS) in Burkina Faso have successfully completed initial safety evaluations in 30 adult Burkinabés as the first phase of a clinical trial of Sanaria PfSPZ-LARC2 Vaccine, which is designed to prevent infection with Plasmodium falciparum malaria.

3 Jun 2025

Asthma drug once hoped to treat alcohol use disorder fails to meet expectations in UCLA trial

A drug that once showed promise as a treatment for alcohol use disorder did not work as expected, a new UCLA clinical trial found.

3 Jun 2025

THP regimen achieves high response rates in HER2 positive breast cancer patients

Patients with Stage II and III (early-stage) HER2+ breast cancer usually undergo pre-operative therapy with multi-agent chemotherapy in combination with anti-HER2 antibodies, followed by surgery.

2 Jun 2025

First-in-class antibody-drug conjugate shows high response rates in rare blood cancer trial

The first-in-class antibody-drug conjugate (ADC) pivekimab sunirine (PVEK) demonstrated promising efficacy and high response rates for patients with blastic plasmacytoid dendric cell neoplasm (BPDCN), according to data from a Phase I/II study led by researchers from The University of Texas MD Anderson Cancer Center.

2 Jun 2025

Immunotherapy before surgery boosts long term survival in lung cancer, trial shows

Results from a phase 3 clinical trial published in the New England Journal of Medicine, today (June 2nd) show that patients with lung cancer who received an immunotherapy drug, nivolumab, along with standard chemotherapy before surgery had improved long term survival compared to those who received chemotherapy alone, at 5 years after completing treatment.

2 Jun 2025

Treatment switching guided by liquid biopsy results improves outcomes in advanced breast cancer

A large prospective, randomized clinical trial in patients with advanced breast cancer has found that the use of liquid biopsy blood tests for early detection of a treatment-resistance mutation, followed by a switch to a new type of treatment, substantially extends the period of tumor control compared to standard care.

1 Jun 2025

Adding immunotherapy to chemotherapy after surgery improves survival in colon cancer

Colon cancer is the third most prevalent form of cancer in the U.S., and while screening has helped detect and prevent colon cancer from spreading, major advancements in treating colon cancer have lagged.

1 Jun 2025

Avelumab and cetuximab combination shows promise in phase II skin cancer trial

A phase II clinical trial led by the Alliance for Clinical Trials in Oncology has met its primary endpoint, demonstrating that the combination of avelumab and cetuximab improved progression-free survival (PFS) compared to avelumab alone in patients with advanced cutaneous squamous cell carcinoma (cSCC).

1 Jun 2025

Dual-target CAR T cell therapy shrinks tumors in aggressive brain cancer

A dual-target CAR T cell therapy approach shows promise for slowing tumor growth in a notoriously aggressive and fast-growing brain cancer.

1 Jun 2025

Combination treatment extends progression-free survival in advanced skin cancer

In patients with an advanced type of skin cancer called cutaneous squamous cell carcinoma (cSCC), those who received the combination of the immunotherapy drug avelumab and targeted agent cetuximab had almost four times longer median progression-free survival compared to patients who received avelumab alone, according to the results of a phase 2 trial presented today at the American Society of Clinical Oncology (ASCO) meeting and concurrently published in the Journal of Clinical Oncology.

1 Jun 2025

Universal CAR T cell therapy shows promise for aggressive T cell cancers

A new type of immunotherapy that targets aggressive blood cancers shows promising results alongside manageable side effects, according to the results of an international phase 1/2 clinical trial led by researchers at Washington University School of Medicine in St. Louis.

31 May 2025

Triplet therapy significantly improves survival in BRAF V600E-mutated metastatic colorectal cancer

First-line treatment with the triplet combination of encorafenib, cetuximab and mFOLFOX6 significantly improved survival compared to the standard of care in patients with BRAF V600E-mutated metastatic colorectal cancer, according to new data from the Phase III BREAKWATER trial led by researchers from The University of Texas MD Anderson Cancer Center.

30 May 2025

Drug Trial News

Nicotinamide riboside shows promise in treating Werner syndrome symptoms

New data shows zigakibart sustains proteinuria remission and kidney function in IgA nephropathy

P2Y12 inhibitors linked to lower rates of cardiovascular events compared to aspirin

Type 2 diabetes drug shows improvements for patients with progressive liver disease

AI-designed drug shows early promise for lung fibrosis patients in clinical trial

SWOG S2302 Pragmatica-Lung study demonstrates value of streamlined clinical trials in real world settings

Early camizestrant therapy keeps advanced breast cancer in check

Real world data confirms effectiveness of nirsevimab in young infants with bronchiolitis

PfSPZ-LARC2 malaria vaccine advances to new age groups after successful safety review

Asthma drug once hoped to treat alcohol use disorder fails to meet expectations in UCLA trial

THP regimen achieves high response rates in HER2 positive breast cancer patients

First-in-class antibody-drug conjugate shows high response rates in rare blood cancer trial

Immunotherapy before surgery boosts long term survival in lung cancer, trial shows

Treatment switching guided by liquid biopsy results improves outcomes in advanced breast cancer

Adding immunotherapy to chemotherapy after surgery improves survival in colon cancer

Avelumab and cetuximab combination shows promise in phase II skin cancer trial

Dual-target CAR T cell therapy shrinks tumors in aggressive brain cancer

Combination treatment extends progression-free survival in advanced skin cancer

Universal CAR T cell therapy shows promise for aggressive T cell cancers

Triplet therapy significantly improves survival in BRAF V600E-mutated metastatic colorectal cancer

How can super-resolution technology help study neurotransmission?

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Latest News